Diarrhea is a common event in the clinical history of cancer patients. It can be caused by the presence of tumor or it can be a side effect of treatment. The latter problem is occurring more often because new drugs (CPT-11) or drug combinations (fluorouracil plus interferon or leucovorin) have diarrhea as the dose-limiting toxicity. The clinical use of octreotide, a long-acting somatostatin analogue, seemed to demonstrate an improvement in most diarrheal states induced by tumors (endocrine tumors) or by treatments (short bowel syndrome; chemotherapy-induced diarrhea).
Management of diarrhea induced by tumors or cancer therapy / Cascinu, Stefano. - In: CURRENT OPINION IN ONCOLOGY. - ISSN 1040-8746. - 7:(1995), pp. 325-329.
Management of diarrhea induced by tumors or cancer therapy.
CASCINU, Stefano
1995-01-01
Abstract
Diarrhea is a common event in the clinical history of cancer patients. It can be caused by the presence of tumor or it can be a side effect of treatment. The latter problem is occurring more often because new drugs (CPT-11) or drug combinations (fluorouracil plus interferon or leucovorin) have diarrhea as the dose-limiting toxicity. The clinical use of octreotide, a long-acting somatostatin analogue, seemed to demonstrate an improvement in most diarrheal states induced by tumors (endocrine tumors) or by treatments (short bowel syndrome; chemotherapy-induced diarrhea).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
